Not all patients with CLL call for therapy. Regardless of all current advancements, the iwCLL still recommends watchful observation for patients with asymptomatic disease.86 This advice is based on a minimum of two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Dilisen